Shift Bioscience

Shift Bioscience is a biotechnology company developing cell rejuvenation therapies to reverse age-driven diseases by targeting the aging cell. The company has built a best-in-class target discovery platform combining a novel aging clock (AC4) and virtual cell model to remove the primary bottleneck for discovery of cellular aging and rejuvenation targets, enabling identification of hundreds of novel targets linked to disease states. Its lead product, SB101, is an anti-fibrotic siRNA therapeutic that reverses epigenetic aging clocks in multiple cell types through a genetically validated fibrosis pathway, with first-in-class opportunities in liver fibrosis and expansion potential to secondary fibrosis in lung and heart. The company has published research on AI virtual cells for genetic perturbation modeling and holds a comprehensive IP package with patent life extending to 2046. Founded in 2017 and headquartered in Cambridge, UK, with computational operations in Toronto, Canada, Shift Bioscience has raised approximately $28.6M in seed funding from investors including BGF, F-Prime Capital, Kindred Capital, and Healthspan Capital.